Tag
Moderna's mRNA flu vaccine mFLUSIVA received FDA approval for adults over 50, marking the first mRNA-based flu shot. However, uncertainty remains due to the CDC advisory panel being defunct amid litigation, affecting coverage recommendations.
Moderna announced FDA approval of mFLUSIVA (mRNA-1010), a seasonal influenza vaccine for adults 50 and older, following unanimous advisory committee recommendations.
This article provides an overview of the current landscape of AI-enabled medical devices that have received FDA approval, highlighting trends and regulatory progress in healthcare technology.